Summary of the interim report
The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.

Third quarter 2023 for the group
Income amounted to TSEK 0 (0).
Loss before tax totalled TSEK 11,953 (loss: 14,456).
Loss per share was SEK 0.02 (loss: 0.11).

First nine month 2023 for the group
Income amounted to TSEK 0 (0).
Loss before and tax totalled TSEK 46,192 (loss: 49,781).
Loss per share was SEK 0,11 (loss: 0,36)

Third quarter 2023 for the parent company
Income amounted to TSEK 0 (0).
Loss before tax totalled TSEK 8,916 (loss: 9,197).
Loss per share was SEK 0.02 (loss: 0.07).

First nine month 2023 for the parent company
Income amounted to TSEK 0 (0).
Loss before tax totalled TSEK 30,469 (loss: 31,786).
Loss per share was SEK 0,08 (loss: 0,23).
At September 30, 2023, the equity/assets ratio was 82 % (59).

Significant events in the third quarter of 2023
Xintela publishes the outcome of the rights issue. (July 4, 2023)
Xintela gets product patent in USA for chondrocyte-based products. (August 15, 2023)

Significant events after the end of the period
Xintela’s stem cell product, XSTEM, has been assessed as safe at all dose levels in knee osteoarthritis clinical study. (October 10, 2023)

The complete report is available for download below and on the company’s website www.xintela.se/en/investors#reports.

Contacts

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB.

Attachments

Xintela 2023 Q3 EN

© Modular Finance, source Nordic Press Releases